We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · November 09, 2022

Osimertinib Plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Patients With EGFR–Mutated MET-Amplified NSCLC

Cancer Discovery


Additional Info

Cancer Discovery
Osimertinib+Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor Mutated MET-Amplified Non-Small Cell Lung Cancer: TATTON
Cancer Discov 2022 Oct 20;[EPub Ahead of Print], RJ Hartmaier, AA Markovets, MJ Ahn, LV Sequist, JY Han, BC Cho, HA Yu, SW Kim, JC Yang, JS Lee, WC Su, DM Kowalski, S Orlov, S Ren, P Frewer, X Ou, DA Cross, N Kurian, M Cantarini, PA Janne

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading